ÂÜÀòÂÒÂ×

Fabio Pucci has been an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer, since 2021. He is responsible for search and evaluation, as well as healthcare focused investment across a wide spectrum of therapeutic modalities and indications. Fabio currently serves as board director or observer for Capstan, Immunitas, Indapta, Kojin, and, previously, for Hemab. Prior to Leaps by Bayer, Fabio worked at RA Capital, a biotech multistage investment fund, and worked at the Francis Crick Institute in London as a cancer researcher. Fabio obtained his PhD from the Wellcome Trust Centre for Cell Biology and his MBA from the London Business School.